Sunday 05 February 2023 - 08:59
In Business 43 Years - Since 1980
Sale: 25% Off !!
For Online Shopping Cart Orders Only
In-Stock Sizes Only - Limited Time Only
See Check-out Page For Further Details
FREE SHIPPING TO THE U.S. AND 32 OTHER COUNTRIES! [Read more].
Search:
A-2311 Alectinib, Hydrochloride Salt, >99%
Synonyms : [AF802] [CH5424802]
Related Terms : [Alecensa]
- Size
- US $
- €
- £
- ¥
- 25 mg
- 49
- 45
- 40
- 6,400
- In stock
- 50 mg
- 63
- 58
- 52
- 8,300
- In stock
- 100 mg
- 92
- 85
- 76
- 12,100
- In stock
- 200 mg
- 139
- 128
- 115
- 18,200
- In stock
- 250 mg
- 161
- 148
- 133
- 21,100
- In stock
- 500 mg
- 259
- 239
- 214
- 34,000
- In stock
- 1 g
- 378
- 349
- 313
- 49,600
- In stock
- 2 g
- 684
- 632
- 567
- 89,700
- In stock
- 5 g
- 1,240
- 1,145
- 1,029
- 162,700
- In stock
Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.
To receive a Formal Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities
Free Shipping and Handling to the U.S. and 32 Other Countries
- M.W. 519.08
- C30H34N4O2HCl
- [1256589-74-8]
Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO.
- This research compound is the hydrochloride salt form of alectinib. Please see the free base form of alectinib, Cat. No. A-2300, Alectrinib, Free Base, for further technical Information.
- This product is the hydrochloride salt, whose CAS number is given above. The CAS number of Alectinib, Free Base is 1256580-46-7.
- Related CAS numbers: 1256590-18-7 for the hydrochloride salt, equivalent ratio not specified; 1358953-69-1 for the methanesulfonate salt, equivalent ratio not specified; and 1820744-87-3 for the hydrochloride hydrate salt (1:1:1).
- Another CAS number previously assigned to alectinib, namely 1416163-60-4, has been deleted by CAS and is no longer in use.
- Alectinib (as the free base) is the active ingredient in the drug product sold under the trade name Alecensa®. This drug is currently approved in at least one country for use in patients with anaplastic lymphoma kinase -positive metastatic non-small cell lung cancer. NOTE: THE ALECTINIB SOLD BY LC LABORATORIES FOR RESEARCH IS NOT ALECENSA®, AND IS NOT FOR HUMAN USE.
- Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
- This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
